1. Qi D, Liu Y, Li J, Huang JH, Hu X, Wu E. Salinomycin as a potent anticancer stem cell agent: State of the art and future directions.Med Res Rev. 2022;42(3):1037-1063. doi:10.1002/med.21870
2. Hamaï A, Cañeque T, Müller S, et al. An iron hand over cancer stem cells. Autophagy. 2017;13(8):1465-1466. doi:10.1080/15548627.2017.1327104
3. Dewangan J, Srivastava S, Rath SK. Salinomycin: A new paradigm in cancer therapy.Tumour Biol. 2017;39(3):1010428317695035. doi:10.1177/ 1010428317695035
4. Zhou Y, Zhou Y, Shingu T, et al. Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis.J Biol Chem. 2011;286(37):32843-32853. doi: 10.1074/jbc.M111.260935
5. Tamada M, Nagano O, Tateyama S, et al. Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells.Cancer Res. 2012;72(6):1438-1448. doi:10.1158/ 0008-5472.CAN-11-3024
6. Chae YC, Kim JH. Cancer stem cell metabolism: target for cancer therapy. BMB Rep. 2018;51(7):319-326. doi:10.5483/bmbrep.2018.51.7.112
7. Janiszewska M, Suvà ML, Riggi N, et al. Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes Dev. 2012;26(17):1926-1944. doi:10.1101/gad.188292.112
8. Lagadinou ED, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.Cell Stem Cell. 2013;12(3):329-341. doi:10.1016/j.stem.2012.12.013
9. Jang YY, Sharkis SJ. A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. Blood. 2007;110(8):3056-3063. doi:10.1182/blood-2007-05-087759
10. Wang Y, Steinbeisser H. Molecular basis of morphogenesis during vertebrate gastrulation.Cell Mol Life Sci. 2009;66(14):2263-2273. doi:10. 1007/s00018-009-0018-2
11. Jain S, Annett SL, Morgan MP, Robson T. The cancer stem cell niche in ovarian cancer and its impact on immune surveillance.Int J Mol Sci. 2021;22(8):4091. doi:10.3390/ijms22084091
12. McAuliffe SM, Morgan SL, Wyant GA, et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A. 2012;109(43):E2939-E2948. doi:10. 1073/pnas.1206400109
13. Allenspach EJ, Maillard I, Aster JC, Pear WS. Notch signaling in cancer. Cancer Biol Ther. 2002;1(5):466-476. doi:10.4161/cbt.1.5.159
14. Nusse R, Clevers H. Wnt/ß-Catenin Signaling, Disease, and Emerging Therapeutic Modalities.Cell. 2017;169(6):985-999. doi:10.1016/j.cell. 2017.05.016
15. Duchartre Y, Kim YM, Kahn M. The Wnt signaling pathway in cancer. Crit Rev Oncol Hematol. 2016;99:141-149. doi:10.1016/j.critrevonc.2015. 12.005
16. Bolouri H, Farrar JE, Triche T Jr, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions.Nat Med. 2018; 24(1):103-112. doi:10.1038/nm.4439
17. Ma Y, Zhang P, Wang F, Yang J, Yang Z, Qin H. The relationship between early embryo development and tumourigenesis.J Cell Mol Med. 2010;14(12):2697-2701. doi:10.1111/j.1582-4934.2010.01191.x
18. Peng D, Fu M, Wang M, Wei Y, Wei X. Targeting TGF-ß signal transduction for fibrosis and cancer therapy. Molecular Cancer. 2022; 21(1):104.
19. Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer.Nat Rev Clin Oncol. 2018;15(4):234-248. doi: 10.1038/nrclinonc.2018.8
20. Harte MT, Gorski JJ, Savage KI, et al. NF-?B is a critical mediator of BRCA1-induced chemoresistance.Oncogene. 2014;33(6):713-723. doi: 10.1038/onc.2013.10
21. Gonzalez-Torres C, Gaytan-Cervantes J, Vazquez-Santillan K, et al. NF-?B participates in the stem cell phenotype of ovarian cancer cells.Arch Med Res. 2017;48(4):343-351. doi:10.1016/j.arcmed.2017.08.001
22. Parajuli B, Lee HG, Kwon SH, et al. Salinomycin inhibits Akt/NF-?B and induces apoptosis in cisplatin resistant ovarian cancer cells.Cancer Epidemiol. 2013;37(4):512-517. doi:10.1016/j.canep.2013.02.008
23. Bregenzer ME, Horst EN, Mehta P, Novak CM, Repetto T, Mehta G. The role of cancer stem cells and mechanical forces in ovarian cancer metastasis.Cancers (Basel). 2019;11(7):1008. doi:10.3390/cancers 11071008
24. Yeung TL, Leung CS, Wong KK, et al. TGF-ß modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment.Cancer Res. 2013;73(16):5016-5028. doi:10.1158/ 0008-5472.CAN-13-0023
25. Xiang T, Long H, He L, et al. Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer.Oncogene. 2015;34(2):165-176. doi:10.1038/onc. 2013.537
26. Long H, Xie R, Xiang T, et al. Autocrine CCL5 signaling promotes invasion and migration of CD133+ ovarian cancer stem-like cells via NF-?B-mediated MMP-9 upregulation.Stem Cells. 2012;30(10):2309-2319. doi:10.1002/stem.1194
27. Varas-Godoy M, Rice G, Illanes SE. The crosstalk between ovarian cancer stem cell niche and the tumor microenvironment.Stem Cells Int. 2017;2017:5263974. doi:10.1155/2017/5263974
28. Wang D, Xiang T, Zhao Z, et al. Autocrine interleukin-23 promotes self-renewal of CD133+ ovarian cancer stem-like cells.Oncotarget. 2016;7(46):76006-76020. doi:10.18632/oncotarget.12579
29. Tang S, Xiang T, Huang S, et al. Ovarian cancer stem-like cells differentiate into endothelial cells and participate in tumor angiogenesis through autocrine CCL5 signaling.Cancer Lett. 2016;376(1):137-147. doi:10.1016/j.canlet.2016.03.034
30. Klemba A, Purzycka-Olewiecka JK, Wcislo G, et al. Surface markers of cancer stem-like cells of ovarian cancer and their clinical relevance.Contemp Oncol (Pozn). 2018;22(1A):48-55. doi:10.5114/wo.2018.73885
31. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.N Engl J Med. 2012;366(10):883-892. doi:10.1056/NEJMoa1113205
32. Prasetyanti PR, Medema JP. Intra-tumor heterogeneity from a cancer stem cell perspective.Mol Cancer. 2017;16(1):41. doi:10.1186/s12943-017-0600-4
33. Medema JP. Cancer stem cells: the challenges ahead.Nat Cell Biol. 2013; 15(4):338-344. doi:10.1038/ncb2717
34. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells.Nature. 2004;432(7015):396-401. doi:10.1038/nature03128
35. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells.Proc Natl Acad Sci U S A. 2003;100(7):3983-3988. doi:10.1073/pnas.0530291100
36. Menke-van der Houven van Oordt CW, Gomez-Roca C, van Herpen C, et al. First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors. Oncotarget. 2016;7(48):80046-80058. doi:10.18632/oncotarget. 11098
37. Kowalski M, Entwistle J, Cizeau J, et al. A phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients.Drug Des Devel Ther. 2010;4:313-320. doi:10. 2147/DDDT.S14071
38. James MI, Iwuji C, Irving G, et al. Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy. Cancer Lett. 2015;364(2):135-141. doi:10.1016/j.canlet. 2015.05.005
39. Rodon J, Argilés G, Connolly RM, et al. Phase 1 study of single-agent WNT974, a first-in-class porcupine inhibitor, in patients with advanced solid tumours. Br J Cancer. 2021;125(1):28-37. doi:10.1038/s41416-021-01389-8
40. Chiorean EG, LoRusso P, Strother RM, et al. A phase I first-in-human study of enoticumab (REGN421), a fully human delta-like ligand 4 (Dll4) monoclonal antibody in patients with advanced solid tumors.Clin Cancer Res. 2015;21(12):2695-2703. doi:10.1158/1078-0432.CCR-14-2797
41. Sun HR, Wang S, Yan SC, et al. Therapeutic strategies targeting cancer stem cells and their microenvironment.Front Oncol. 2019;9:1104. doi: 10.3389/fonc.2019.01104
42. Tauriello DVF, Sancho E, Batlle E. Overcoming TGFß-mediated immune evasion in cancer.Nat Rev Cancer. 2022;22(1):25-44. doi:10. 1038/s41568-021-00413-6
43. Strauss J, Heery CR, Schlom J, et al. Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFß, in advanced solid tumors.Clin Cancer Res. 2018;24(6):1287-1295. doi:10.1158/1078-0432.CCR-17-2653
44. Shintani Y, Fujiwara A, Kimura T, et al. IL-6 secreted from cancer-associated fibroblasts mediates chemoresistance in NSCLC by increasing epithelial-mesenchymal transition signaling.J Thorac Oncol. 2016;11(9):1482-1492. doi:10.1016/j.jtho.2016.05.025
45. Rock KL, Reits E, Neefjes J. Present yourself! By MHC class I and MHC class II molecules.Trends Immunol. 2016;37(11):724-737. doi:10.1016/j.it.2016.08.010
46. Jachetti E, Caputo S, Mazzoleni S, et al. Tenascin-C protects cancer stem-like cells from immune surveillance by arresting T-cell activation.Cancer Res. 2015;75(10):2095-2108. doi:10.1158/0008-5472.CAN-14-2346
47. Zhong M, Zhong C, Cui W, et al. Induction of tolerogenic dendritic cells by activated TGF-ß/Akt/Smad2 signaling in RIG-I-deficient stemness-high human liver cancer cells.BMC Cancer. 2019;19(1):439. doi:10.1186/s12885-019-5670-9
48. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.Nat Rev Cancer. 2016;16(5):275-287. doi:10.1038/nrc.2016.36
49. Garris CS, Arlauckas SP, Kohler RH, et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-? and IL-12.Immunity. 2018;49(6):1148-1161.e7. doi:10. 1016/j.immuni.2018.09.024
50. Verma V, Shrimali RK, Ahmad S, et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hicells and anti-PD-1 resistance. Nat Immunol. 2019;20(9):1231-1243. doi:10.1038/s41590-019-0441-y
51. Madan V, Koeffler HP. Differentiation therapy of myeloid leukemia: four decades of development.Haematologica. 2021;106(1):26-38. doi:10. 3324/haematol.2020.262121
52. Fallenberg EM, Schmitzberger FF, Amer H, et al. Contrast-enhanced spectral mammography vs. mammography and MRI - clinical performance in a multi-reader evaluation.Eur Radiol. 2017;27(7):2752-2764. doi:10.1007/s00330-016-4650-6
53. Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796-807. doi:10.1016/S1470-2045(20) 30157-1
54. Mellinghoff IK, Penas-Prado M, Peters KB, et al. Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; results of a first-in-human phase I trial.Clin Cancer Res. 2021;27(16):4491-4499. doi:10.1158/1078-0432.CCR-21-0611
55. Eder JP, Doroshow DB, Do KT, et al. Clinical efficacy of olaparib in IDH1/IDH2-mutant mesenchymal sarcomas.JCO Precis Oncol. 2021;5: 466-472. doi:10.1200/PO.20.00247